1
*** Text Omitted and Filed Separately
Confidential Treatment Requested
Under 17 C.F.R. Sections 200.80,
200.83 and 230.406.
EXHIBIT 10.34
[UNIVERSITY OF CALIFORNIA LETTERHEAD]
February 2,1998
Carl F. Bobkoski
Executive Vice President
Signal Pharmaceuticals, Inc.
5555 Oberlin Drive
San Diego, CA 92121
RE: Second Amendment to Exclusive License Agreement for:
Methods for Production of Neuroblasts and Testing Drugs...
UC Case No. 92-116 etc.: UC Agreement Control No. 93-04-0786
Dear Carl:
I write regarding a proposed designated sublicense agreement, which Signal
Pharmaceuticals, Inc. "Signal") is negotiating for the [***] Technologies (as
defined in the subject License Agreement) with a certain other party
("Designated Sublicensee"). Signal wishes to issue this sublicense with a
royalty base that differs from the royalty base defined in the License Agreement
and on other terms and conditions which vary from the License Agreement.
Accordingly:
The Regents agrees to waive certain provisions of the License Agreement solely
for this designated sublicense in consideration of Signal agreeing that
(capitalized terms should have the meaning set forth herein, if not specified
herein, the meaning defined in the above referenced License Agreement):
(a) The designated sublicense grant will be confined to a field allowing
the Designated Sublicensee to use the [***] Technologies in connection
with [***]
***Confidential Treatment Requested
2
Carl F. Bobkoski
February 2, 1998
Page 2
(b) Signal will pay The Regents an earned royalty on Net Sales of
Licensed Product sold by the Designated Sublicensee, its affiliates and
sublicensees as set forth in Appendix A hereto; accordingly, solely for
purposes of the designated sublicense agreement. Paragraphs 5.1 through
5.3 and 5.9 of the License Agreement are hereby superseded by the terms
and conditions set forth in Appendix A.
(c) Upon termination of the License Agreement or reduction of Signal's
license under the License Agreement to non-exclusive, for any reason, The
Regents shall accept assignment of this designated sublicense, as provided
for in the First Amendment to Exclusive License Agreement for [***]
effective June 22, 1997. Notwithstanding the foregoing, The Regents shall
accept assignment of this sublicense even if Signal was in breach of the
License Agreement when entering into the sublicense.
(d) The designated sublicense agreement will require that Sublicensee
(itself or through a designee) develop at least [***] as follows:
- [***]
- [***]
- [***]
- [***]
Notwithstanding the foregoing, the designated sublicense agreement may provide
for reasonable extensions of the foregoing diligence deadlines, if despite
diligent efforts such deadline is or may not be met. However, in the event that
The Regents accepts assignment of the sublicense, The Regents shall not be
required to provide any extension of the diligence deadlines and any extension
of the diligence deadlines shall be at the sole discretion of The Regents.
Apart from the above-specified changes, the subject sublicense agreement will
adhere to all the sublicensing provisions of the License Agreement. However, to
the extent this letter and the License Agreement conflict solely with respect
to the designated sublicense agreement this letter will control.
***Confidential Treatment Requested
3
Carl F. Bobkoski
February 2, 1998
Page 3
If you agree to the terms of this letter, please sign both enclosed originals
and return them to me. I will return a fully executed original to you for your
records.
Sincerely,
/s/ PATRICIA ANDERSON COTTON, PH.D.
-----------------------------------
Patricia Anderson Cotton, Ph.D.
Licensing Officer
______________________________________________________________________________
SIGNAL PHARMACEUTICALS THE REGENTS OF THE UNIVERSITY
INC.: OF CALIFORNIA:
By: /s/ CARL F. BOBKOSKI By: /s/ TERENCE A. FEUERBORN
------------------------------- -------------------------------
(Signature) (Signature)
Name: Carl F. Bobkoski Name: Terence A. Feuerborn
Title: Executive Vice President Title: Executive Director
Office of Research Administration
and Technology Transfer
Date: Feb. 13, 98 Date: 3-2-98
----------------------------- -----------------------------
[ILLEGIBLE]
/s/ P. Martin Simpson, Jr. 3-Jan 98
----------------------- --------
P. Martin Simpson, Jr. Date
Resident Counsel
Office of Technology Transfer
University of California
4
APPENDIX A TO SECOND AMENDMENT DATED FEBRUARY 2, 1998
Signal and The Regents agree that solely for purposes of the designated
sublicense agreement:
1. The following terms defined in Paragraphs 1.2, 1.3, 1.4 and 1.5 of the
License Agreement shall have the following meanings:
1.2 "Licensed Product" means any product, composition or material (i) the
sale of which would, but for the licenses granted to the Designated
Sublicensee, infringe a Valid Claim within The Regents' Patent Rights in the
country for which such product, composition or material is sold or (ii) is
manufactured or administered to a patient by a Licensed Method.
1.3 "Licensed Method" means any method (i) the practice of which would,
but for the license granted to Designated Sublicensee, infringe a Valid Claim
within Regents' Patent Rights or (ii) consisting of a method of [***]
1.4 "Net Sales" means the total amount invoiced to third parties on sales of
Licensed Products by Designated Sublicensee, its affiliates or sublicensees,
less the following reasonable and customary deductions to the extent applicable
to such invoiced amounts: (i) all trade, cash and quantity credits, discounts,
refunds or government rebates; (ii) amounts for claims, allowances or credits
for returns, retroactive price reductions, or chargebacks; (iii) packaging,
handling fees and prepaid freight, sales taxes, duties and other governmental
charges (including value added tax); and (iv) provisions for uncollectible
accounts determined in accordance with reasonable accounting practices,
consistently applied to all products of the selling party; provided, however,
that in the case of Patient-Specific Licensed Products, "Net Sales" shall equal
[***] of the foregoing amounts (after the deductions described in (i) through
(iv) above). For purposes of the foregoing, it is understood that Net Sales
shall include only the amount invoiced for materials consisting of Licensed
Products (less the foregoing deductions and adjustments) and shall not include
charges related to services [***] performed in connection with the sale of such
Licensed Products; accordingly, Net Sales shall not include, without limitation,
charges for [***] or the like. For the removal of doubt, Net Sales shall not
include sales by Sublicensee to its affiliates for resale, provided that if
Sublicensee sells a Licensed Product to an affiliate for resale, Net Sales shall
include the amounts invoiced by such affiliate to third parties on the resale of
such Licensed Product.
1.5 "Affiliate" means any corporation or other business entity in which
the Licensee or Designated Sublicensee owns or controls, directly or
indirectly, at least fifty (50%) of the outstanding stock or other voting
rights entitled to elect directors; provided however, that any country where
the local law shall not permit foreign equity participation of at least 50%,
then an
***Confidential Treatment Requested
5
"Affiliate" shall include any company in which the Licensee or Sublicensee owns
or controls, directly or indirectly, the maximum percentage of such outstanding
stock or voting rights permitted by local law.
2. The following definitions are added to Article I (Definitions) of the
License Agreement:
1.9 [***]
2.0 "Valid Claim" shall mean a claim of an issued and unexpired patent or
a claim of a pending patent application within Regents' Patent Rights which has
not been held unpatentable, invalid or unenforceable by a court or other
government agency of competent jurisdiction and has not been admitted to be
invalid or unenforceable through reissue, re-examination, disclaimer or
otherwise. Notwithstanding the foregoing, if a claim of a pending patent
application within Regents' Patent Rights has not issued as a claim of an
issued patent within Regent's Patent Rights, on or before [***]
such pending claim shall not be a Valid Claim for purposes of the sublicense
agreement unless and until such claim issues.
3. Paragraphs 5.1, 5.2, 5.3 and 5.9 of the License Agreement shall be removed
and replaced with the following:
5.1(a) The Licensee shall pay The Regents an earned royalty of [***] of
the Net Sales of Licensed Product sold by the Designated Sublicensee, its
Affiliates or sublicensees; provided that the earned royalty shall be [***] of
the Net Sales of Licensed Products, if such Net Sales by Licensee, its
Affiliates and sublicensees (including without limitation, Designated
Sublicensee, its Affiliates and sublicensees) are less than [***] per year in
any given calendar year of sales.
5.1(b) The earned royalty due under Paragraph 5.1(a) above with respect
to a Licensed Product which is not covered by any Valid Claim but is
manufactured or administered to patients using a Licensed Method not covered by
a Valid Claim shall be [***].
5.2 Royalties shall continue under Paragraph(s) 5.1(a) and 5.1(b) above
with respect to each Licensed Product, (i) on a country-by-country basis for so
long as the sale of such Licensed Product would, but for the license granted to
Designated Sublicensee, infringe a Valid Claim within the Regents' Patent rights
in such country or (ii) with respect to a Licensed Product(s) not covered by any
Valid Claim but that is manufactured or administered to patients using a
Licensed Method not covered by a Valid Claim for [***] from the date of first
commercialization of the first such Licensed Product in any country.
***Confidential Treatment Requested
6
5.3 Earned royalties due on Net Sales of Licensed Products by Designated
Sublicensee, its affiliates or sublicensees shall be deemed accrued in the
quarter in which Licensee receives payment from the Sublicensee with respect to
such Net Sales, but in no event later than the quarter following the quarter in
which Net Sales are made by the Sublicensee, its affiliates or sublicensee.